Merge Healthcare and MEDRAD announce an expansion of their EU Distribution Agreement for CADstream

Merge Healthcare (NASDAQ: MRGE), a health IT solutions leader, and MEDRAD, a leading provider of medical devices and services for diagnostic imaging, today announced an expansion of their European Union Distribution Agreement for CADstream, a dedicated CAD system for MRI. The expanded Distribution Agreement now allows MEDRAD to distribute CADstream in France, as well as the United Kingdom, Germany and Italy; some of the fastest-growing markets for CAD in the EU.

"MEDRAD has spearheaded the availability of this important technology in Europe,” said Paul Budak, president of Merge CAD (formerly Confirma). "As breast and prostate MRI study volumes increase, physicians are searching for systems that will improve the workflow of time-intensive studies. CADstream has been a market leader in breast MRI CAD in the U.S. for some time, and MEDRAD is a great partner to expand its deployment in the EU."

"CADstream complements the MEDRAD product portfolio and customers in France are requesting the product,” said Anthony Cinalli, executive director, radiology marketing, MEDRAD. “We are happy to now offer CADstream – which is reported to be the standard in breast MRI CAD – to the French market.”

In the 2008 European Markets for Computer Aided Detection report published by Frost and Sullivan, CAD is considered a must-have in 2010 in many EU countries. The Merge team has been ramping up educational efforts for EU radiologists as a result. Workshops on breast MRI have been held in Germany and the U.K., and a course is scheduled for France in November. Education schedules and online registration can be found at http://www.merge.com/cad/benefits/education.aspx.

“CAD has become an integral part of breast MRI study interpretation,” said Dr. Michael Middleton, Assistant Professor, Department of Radiology, University of San Diego, California (UCSD). Dr. Middleton led the Merge-sponsored Practical Breast MRI with CAD workshop in London in September.

 

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New UCL hub to advance cancer detection with imaging tech